Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
Yan‐Ling He, William G. Haynes, Charles D. Meyers, et al.
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. 6, pp. 1311-1321
Closed Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Young Jin Tak, Sang Yeoup Lee
Current Obesity Reports (2021) Vol. 10, Iss. 1, pp. 14-30
Open Access | Times Cited: 264
Glucose transporters in the small intestine in health and disease
Hermann Koepsell
Pflügers Archiv - European Journal of Physiology (2020) Vol. 472, Iss. 9, pp. 1207-1248
Open Access | Times Cited: 197
Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management
Thomas Marjot, Ahmad Moolla, Jeremy Cobbold, et al.
Endocrine Reviews (2019) Vol. 41, Iss. 1, pp. 66-117
Open Access | Times Cited: 194
Cu Single Atom Nanozyme Based High‐Efficiency Mild Photothermal Therapy through Cellular Metabolic Regulation
Mengyu Chang, Zhiyao Hou, Man Wang, et al.
Angewandte Chemie International Edition (2022) Vol. 61, Iss. 50
Closed Access | Times Cited: 128
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 37
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 3
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angeliki M. Angelidi, Matthew J. Belanger, Alexander Kokkinos, et al.
Endocrine Reviews (2021) Vol. 43, Iss. 3, pp. 507-557
Open Access | Times Cited: 81
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
Stephen A. Harrison, Federico Pérez Manghi, William B. Smith, et al.
Nature Medicine (2022) Vol. 28, Iss. 7, pp. 1432-1438
Open Access | Times Cited: 50
Adipose tissue, systematic inflammation, and neurodegenerative diseases
Ludovico Migliolo, AnaPaula de A. Boleti, Pedro Henrique de Oliveira Cardoso, et al.
Neural Regeneration Research (2022) Vol. 18, Iss. 1, pp. 38-38
Open Access | Times Cited: 46
Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial
Jiaqi Zhang, Chuan Xing, Xiangyi Cheng, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 39
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 12
<p>Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide</p>
Bryce C. Simes, Gordon G. MacGregor
Diabetes Metabolic Syndrome and Obesity (2019) Vol. Volume 12, pp. 2125-2136
Open Access | Times Cited: 71
Obesity medications in development
Candida J. Rebello, Frank L. Greenway
Expert Opinion on Investigational Drugs (2019) Vol. 29, Iss. 1, pp. 63-71
Open Access | Times Cited: 58
Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
Gianluca Svegliati‐Baroni, Bárbara G. Patrício, Gessica Lioci, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 16, pp. 5820-5820
Open Access | Times Cited: 54
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
V. A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi
Biomedicines (2022) Vol. 10, Iss. 2, pp. 274-274
Open Access | Times Cited: 37
Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases
Yun Seok Kim, Sang Geon Kim
Clinical and Molecular Hepatology (2020) Vol. 26, Iss. 4, pp. 715-727
Open Access | Times Cited: 45
Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure
Rudolf A. de Boer, Julio Núñez, Plamen Kozlovski, et al.
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 7, pp. 1346-1356
Open Access | Times Cited: 40
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double‐blind, phase 2 trial
Susanne Tan, Stanislav Ignatenko, Frank Wagner, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 11, pp. 2595-2599
Open Access | Times Cited: 40
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
Hao Chen, Yang Zhou, Haiping Hao, et al.
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 8, pp. 724-745
Closed Access | Times Cited: 5
Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation
Cong Xie, Karen L. Jones, Christopher K. Rayner, et al.
Pharmaceutics (2020) Vol. 12, Iss. 9, pp. 790-790
Open Access | Times Cited: 39
The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
Emily Brown, John Wilding, Uazman Alam, et al.
Annals of Medicine (2020) Vol. 53, Iss. 1, pp. 2072-2089
Open Access | Times Cited: 39
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity
Harold Bays, Plamen Kozlovski, Qing Shao, et al.
Obesity (2020) Vol. 28, Iss. 5, pp. 870-881
Open Access | Times Cited: 34
Liver-targeting drugs and their effect on blood glucose and hepatic lipids
Amalia Gastaldelli, Norbert Stefan, Hans‐Ulrich Häring
Diabetologia (2021) Vol. 64, Iss. 7, pp. 1461-1479
Open Access | Times Cited: 31
Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis
Tobias Täger, Lutz Frankenstein, Dan Atar, et al.
Clinical Research in Cardiology (2021) Vol. 111, Iss. 4, pp. 428-439
Open Access | Times Cited: 31
Astragalus polysaccharide alleviates type 2 diabetic rats by reversing the glucose transporters and sweet taste receptors/GLP-1/GLP-1 receptor signaling pathways in the intestine-pancreatic axis
Ze‐Min Yang, Ying Wang, Siyu Chen
Journal of Functional Foods (2020) Vol. 76, pp. 104310-104310
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top